Men's Health · 6 min read
Testosterone Therapy Options: Injections, Gels, and Pellets Compared

Testosterone therapy comes in several forms. Here is how injections, gels, and pellets actually compare on evidence, risk, and daily life.
Dr. Jezwah Harris · November 16, 2026
If a lab-confirmed low testosterone level and your symptoms point toward treatment, the next question is usually not whether to start therapy, but which form to use. Testosterone replacement comes as injections, topical gels, and subcutaneous pellets, and each one behaves differently in your body. None is universally "better." Each involves a different tradeoff between how steady your levels stay, how much upkeep it takes, what it costs, and which side effects you are more likely to run into. Here is what the evidence actually shows about each option, so you can have an informed conversation with your clinician rather than guessing.
How the main delivery methods differ
The Endocrine Society's clinical practice guideline on testosterone therapy recommends choosing a formulation based on a combination of patient preference, pharmacokinetics, formulation-specific side effects, treatment burden, and cost, not on a single "best" option (Bhasin et al., 2018). That framing matters, because the three main categories genuinely behave differently.
Injectable testosterone (commonly testosterone cypionate or enanthate, given weekly or every two weeks, or longer-acting testosterone undecanoate given every 10 to 14 weeks) tends to produce the fastest rise in blood levels. Short-acting injections can create a noticeable peak shortly after the dose and a lower trough right before the next one, while longer-acting injectable formulations smooth this out at the cost of needing a clinic visit for administration in many cases.
Topical gels and solutions are applied daily to the skin and are designed to mimic the body's natural daily testosterone rhythm, since levels rise and fall with each application rather than staying flat for weeks. A 2023 pharmacology review notes that transdermal preparations are the only approved forms that preserve testosterone's normal circadian pattern after a single morning dose (Corona et al., 2023).
Subcutaneous pellets are inserted under the skin, usually in the hip or buttock area, during a brief in-office procedure, and then release testosterone steadily for roughly three to five months before they need to be replaced.
Injections: fast-acting, but with real peaks and valleys
Injectable testosterone is often the most affordable option and avoids the daily routine that gels require. Long-acting testosterone undecanoate, for instance, can be spaced out to once every two to three months once a stable dose is found, which some men prefer over a weekly injection schedule.
The tradeoff with short-acting injections is the fluctuation. Testosterone concentrations that spike right after the dose and dip low before the next one can translate into some men noticing their energy, mood, or libido shift across the week rather than staying level. Longer-acting undecanoate largely avoids this problem, though a long-term observational cohort following elderly and younger men on this formulation for a median of over 12 years found that about 40 percent of patients on either age group developed polycythemia (an elevated red blood cell count) at some point during treatment, regardless of age (Abildgaard et al., 2021). That number is a reason hematocrit monitoring is standard with any injectable regimen, not a reason to avoid injections outright.
Gels: no needles, but a transfer risk to think about
For men who prefer to avoid injections or an in-office procedure, daily topical gel is a reasonable alternative, and its steady daily dosing pattern more closely follows how the body naturally produces testosterone than an injection spike does.
The main practical issue is skin-to-skin transfer. In a controlled study of a testosterone-containing gel, researchers measured a clear rise in a female partner's serum testosterone after 15 minutes of close skin contact with an unprotected application site. That transfer dropped substantially, though it did not disappear entirely, when the man showered beforehand or wore a shirt covering the area (Yuen et al., 2018). In practice, this means covering the application site with clothing, washing your hands after applying, and avoiding skin contact with partners, children, or pets for a few hours is not an overcautious suggestion. It is a load-bearing part of using topical testosterone responsibly, especially in a household with women who might be pregnant or children in the home.
Pellets: the least daily effort, with a minor procedure tradeoff
Subcutaneous pellets appeal to men who do not want to think about their testosterone therapy more than a few times a year. Once inserted, they release hormone steadily without daily gel application or injections every week or two.
The downsides are procedural rather than hormonal. Inserting pellets requires a small incision under local anesthetic, and earlier formulations were associated with meaningfully higher rates of pellet extrusion (the pellet working its way back out through the skin) and local infection. A retrospective safety analysis of 292 insertion procedures using a specific modern pellet formulation found an infection rate of 0.3 percent and an extrusion rate of 0.3 percent, substantially lower than the 1.4 to 6.8 percent infection rates and 8.5 to 12 percent extrusion rates reported with an older pellet product (Cavender & Fairall, 2009). That gap is a good example of why "testosterone pellets" as a category covers products with different real-world track records, and it is worth asking which specific pellet your clinic uses.
The hematocrit question that applies to all three
Across every delivery method, elevated hematocrit (too many red blood cells, which thickens the blood and can raise clotting risk) is the side effect clinicians monitor most closely, and the Endocrine Society guideline recommends against starting testosterone therapy at all in men who already have an elevated hematocrit, along with checking it again in the first year of treatment (Bhasin et al., 2018).
There is a common assumption that injections carry a higher erythrocytosis risk than gels because of their sharper peaks. The data on this are more nuanced than that assumption suggests. A 2024 cohort study of nearly 54,000 veterans with type 2 diabetes found that testosterone therapy combined with SGLT-2 inhibitor medications (common in diabetes treatment) roughly doubled to tripled the odds of new erythrocytosis compared with either drug alone, but testosterone's delivery route, topical versus injectable, did not change that risk in their adjusted analysis (Gosmanov et al., 2024). The honest takeaway is that hematocrit needs monitoring no matter which formulation you choose, and if you also take an SGLT-2 inhibitor for diabetes, that monitoring matters even more.
Choosing what fits your life
There is no formulation that wins on every axis. Injections tend to cost less and need less frequent dosing when long-acting, but short-acting versions can produce noticeable highs and lows. Gels avoid needles and procedures but require daily discipline around transfer precautions. Pellets minimize day-to-day effort but require a minor procedure a few times a year and carry some product-dependent risk of extrusion or infection.
The right choice usually comes down to your tolerance for needles versus daily routines versus occasional procedures, how your insurance covers each option, and how your body responds once you start. Most men need to try a formulation for at least two to three months, with a follow-up testosterone and hematocrit check, before they and their clinician know whether it is the right long-term fit.
If low testosterone symptoms have you considering treatment, a telehealth visit with Stonewood Health is a straightforward way to get tested, discuss which delivery method fits your situation, and start monitored treatment without having to find time for an in-person appointment. Learn more about our men's health services. Most major plans are accepted, including Medicare, so this kind of care does not have to be something you pay for separately from the coverage you already have.
Questions
Which testosterone delivery method works fastest?
Injections raise testosterone levels the fastest, often within a day or two, while gels and pellets take longer to reach a steady level. Faster is not automatically better, since a quick rise is also tied to the peak-and-trough swings some men notice with short-acting injections.
Can I switch from one form of testosterone therapy to another?
Yes. Many men change formulations if side effects, cost, or convenience become a problem. Your clinician will usually recheck your testosterone level and hematocrit about six to eight weeks after any switch to confirm the new dose and form are working as expected.
Do testosterone pellets really last three to six months?
Most pellet regimens are dosed to last roughly three to five months, though the exact span depends on your body and metabolism. Some men notice symptoms creeping back in the final weeks before their next insertion is due.
Is injectable testosterone cheaper than gels or pellets?
Injectable testosterone, especially short-acting formulations, is often the least expensive option when covered by insurance, though your actual cost depends on your specific plan and whether you self-inject or need an in-person injection visit. Gels and pellets tend to carry higher list prices.
Will a testosterone gel affect my partner or kids?
It can, through direct skin contact with the application site. Research on transdermal gels has found measurable hormone transfer after close skin contact, which dropped sharply after the user showered or covered the area with clothing. Covering the site and washing your hands after application are standard precautions.
Do all testosterone formulations raise red blood cell counts the same way?
Elevated hematocrit is a known risk across testosterone therapy in general, and long-term studies of injectable testosterone have found a meaningful share of men develop it over time. Some data suggest the risk is similar across delivery routes rather than being driven mainly by the route itself, which is part of why hematocrit monitoring matters regardless of which form you use.
Sources
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2018)
- Corona G, Sparano C, Rastrelli G, Vignozzi L, Maggi M. Developments and challenges for new and emergent preparations for male hypogonadism treatment. Expert Opin Investig Drugs (2023)
- Abildgaard J, Petersen JH, Bang AK, et al. Long-term testosterone undecanoate treatment in the elderly testosterone deficient male: An observational cohort study. Andrology (2021)
- Cavender RK, Fairall M. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis. J Sex Med (2009)
- Yuen F, Wu S, Thirumalai A, et al. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel. Andrology (2018)
- Gosmanov AR, Gemoets DE, Schumacher KA. Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy. J Endocrinol Invest (2024)